PACT Pharma
Hayward
About PACT Pharma
Pact Pharma is a developer of personalized adoptive T cell therapies designed for the eradication of solid tumors.The company's therapies help in the identification of neo-epitopes that serve as private mutations for each patient's cancer as well as creates an opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens, enabling physicians to recognize and remove each patient's cancer cells.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $200.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Jan 2020)
- Website: pactpharma.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Personal Health, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/pact-pharma-55775 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.